echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of the State Food and Drug Administration on Revising the Instructions for Suxiao Jiuxin Pills (No. 12 of 2021)

    Announcement of the State Food and Drug Administration on Revising the Instructions for Suxiao Jiuxin Pills (No. 12 of 2021)

    • Last Update: 2021-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the evaluation results of adverse drug reactions, in order to further protect the safety of public use of drugs, the State Drug Administration has decided to uniformly revise the warnings, [adverse reactions], [taboos] and [precautions] items in the instructions of Suxiao Jiuxin Pills
    .


    The relevant matters are hereby announced as follows:

    1.
    The marketing authorization holder of this product shall revise the instructions in accordance with the relevant regulations such as the "Administrative Measures for Drug Registration" and the corresponding instructions for revision requirements (see appendix), and report to the provincial drug regulatory authority for record before April 13, 2021
    .

    If the revised content involves the label of a drug, it shall be revised together; the instructions and other content of the label shall be consistent with the original approved content
    .


    Drugs produced on the date of filing shall not continue to use the original drug instructions


    2.
    The drug marketing license holder shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on drug use and safety issues, and guide physicians and patients in the rational use of drugs
    .

    3.
    Clinicians should carefully read the revised content of this product's instructions, and when choosing medications, they should conduct adequate benefit/risk analysis based on the newly revised instructions
    .

    4.
    The patient should read the drug insert carefully before taking the medicine.
    If using prescription drugs, they should strictly follow the doctor's advice
    .

    5.
    The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of this product in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and severely investigate and punish violations of laws and regulations in accordance with the law
    .

    Hereby announce
    .


    Attachment: Suxiao Jiuxin Pill instruction revision requirements


    State Food and Drug Administration

    January 14, 2021



    Annex to Announcement No.


    12 of 2021 of the National Medical Products Administration.
    doc



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.